Sign in
SuspendedPhase 1/2

A Study to Investigate Fadraciclib (CYC065), in Subjects With Leukemia or Myelodysplastic Syndrome (MDS)

Key facts

Who runs it
Cyclacel Pharmaceuticals, Inc.
Where
Duarte and Houston, United StatesSee the 2 sites
Trial code
Status
Suspended
Phase
Phase 1/2
People taking part
210 people, planned
Started
22 Oct 2021
Ended
Dec 2024
Type of study
Interventional, 2 groups
Treatments tested
  • fadraciclib
Record updated
8 February 2024
Why it stopped
Slow enrollment and financial limitations

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 22 criteriaShow less

Who can take part

  • Males or females aged ≥ 18 years
  • a) AML/MDS with blasts > 10% in subjects who have had an inadequate response or progression to venetoclax combinations with either HMA or low dose Ara-C or similar venetoclax combinations. or b. CLL in subjects who have received at least 2 lines of therapy, including venetoclax and a BTK inhibitor, who require therapy as per iwCLL criteria
  • Any prior therapy must have been completed at least 2 weeks prior to enrollment on this protocol, and the participant must have recovered to eligibility levels from prior toxicity
  • Hydroxyurea may be used for the first 14 days of Cycle 1 for peripheral blast control. Valproic acid not being used for seizure control should be stopped 72 hours before starting treatment with fadraciclib
  • Any prior therapy with decitabine or azacitidine must have been completed at least 3 weeks prior to enrollment on this protocol
  • Subjects who relapsed post-autologous or post-allogeneic transplant are eligible. Post-transplant subjects must be without active fungal disease or significant acute graft-versus-host disease
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • Women of childbearing potential (WOCBP) must have a negative pregnancy test (urine or serum) within 7 days prior to starting the study drug. Both males and females must agree to use effective birth control during the study (prior to receiving the first dose and for 6 months after the last dose) if conception is possible during this interval
  • Subjects must be able to swallow and retain orally administered medication and not have any clinically significant GI abnormalities that may alter the absorption, such as malabsorption syndrome or major resection of the stomach or bowels
  • Subjects must be able to agree to and sign the informed consent and to comply with the protocol

Who cannot take part

  • Subjects who have not received vaccines for SARS-COV-2 within the last 3 months and have suspected signs and symptoms of COVID-19 or a recent history (within 14 days) of contact with any COVID-19 positive subject/isolation/quarantine or subjects with confirmed COVID-19
  • Subject has received systemic anticancer therapy (including investigational therapy), radiotherapy, or immunotherapy < 14 days or 5 half-lives (whichever is shorter) prior to administration of Dose 1 of study drug on Day 1 or have not recovered from the side effects of such therapy
  • Major surgery/surgical therapy for any cause within 4 weeks of the first dose
  • Subjects with a history of another primary malignancy, other than:; Carcinomas in situ, e.g., breast, cervix, and prostate; Locally excised non-melanoma skin cancer; No evidence of disease from another primary cancer for 2 or more years and has not taken any anticancer treatment in 2 years
  • Diseases that significantly affect GI absorption of fadraciclib
  • Subjects who have impaired cardiac function or clinically significant cardiac disease
  • Presence of active chronic inflammatory bowel disease (ulcerative colitis, Crohn's disease) or GI perforation within 6 months of enrollment
  • Presence of an active infection requiring IV antibiotics
  • Presence of known history of human immunodeficiency virus-1/2 with uncontrolled viral load and on medications that may interfere with metabolism
  • Presence of active hepatitis B virus (HBV) or hepatitis C virus (HCV)
  • Any other clinically significant acute or chronic medical or psychiatric condition or any laboratory abnormality that may increase the risk associated with study drug administration or may interfere with the interpretation of study results
  • Subjects with known active leptomeningeal involvement by AML

Where in United States

  • City of HopeDuarte, United States
  • MD Anderson Cancer CenterHouston, United States

About the trial

What the trial wants to find out

This is a 2-part, phase 1/2, open-label, multicenter study designed to evaluate the safety and efficacy of fadraciclib (formerly CYC065) administered orally BID. This study consists of Phase 1 and Phase 2 components in subjects with Leukemia or Myelodysplastic syndrome (MDS) who have progressed despite having standard therapy or for which no standard therapy exists.

The 2 groups in the trial

  • Phase I Dose escalationTreatment being tested

    Phase 1 = fadraciclib administered orally in escalating doses starting at 50mg bid MWF for 3 weeks of a 4-week cycle. Subsequent cohorts will escalate in dose and schedule until optimized phase 2 dose and schedule is achieved.

    Treatment: fadraciclib

  • Phase 2Treatment being tested

    Recommended fadraciclib phase 2 dose and schedule administered orally in 28-day cycles.

    Treatment: fadraciclib

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase 1/2, Open Label, Multicenter Study to Investigate the Safety and Efficacy of Fadraciclib (CYC065), an Oral CDK 2/9 Inhibitor, in Subjects With Leukemias or Myelodysplastic Syndrome (MDS)
Record updated
8 February 2024